MedTrace Logo

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

NCT06717022 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-12-04

No results posted yet for this study

Summary

Objectives of Study：In this study investigators plan to evaluate the safety and efficacy of MSLN-targeting Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) in the treatment of MSLN-positive advanced solid tumors.

Conditions

  • Mesothelin Positive Tumors

Interventions

BIOLOGICAL

CHT102 allogeneic CAR T cells

CHT102 allogeneic CAR T cells

Sponsors & Collaborators

  • Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

    collaborator INDUSTRY

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2026-06-30
Completion
2039-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717022 on ClinicalTrials.gov